Can botox shots warm up cold fingers? a trial investigates
NCT ID NCT05125029
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether injecting botulinum toxin into the fingers can improve blood flow and temperature in people with Raynaud's phenomenon that has not responded to standard treatments. Participants are randomly assigned to receive a placebo, a low dose, or a higher dose of the toxin. The study measures changes in finger temperature and oxygen levels, along with daily symptom ratings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- botulinum toxin injections into the fingers
- What this could lead to
- If it works, this could offer a new option for people with severe Raynaud's that does not respond to standard medications.
- What could go wrong
- This is a small, early-phase trial with only 24 participants. The effects may be modest, and injections carry risks like pain, infection, or temporary muscle weakness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
24 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 or older * Patients with moderate to severe RP that is not controlled after 3 months of standard medical therapy as prescribed by a Rheumatologist, or severe RP with evidence of tissue loss. Exclusion Criteria: * Patients under the age of 18 * Patients who have previously undergone treatment with BT for RP within the past year * Patients with active infection at the treatment site (active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. WBC, ESR, CRP) * Patients who have undergone prior digital sympathectomy surgery for RP * Patients who have recently altered their medical regimen for RP within the past 4 weeks * Patients with allergy or contraindication to BT injection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Raynaud phenomenon are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital
Atlanta, Georgia, 30322, United States